PHILADELPHIA, April 2, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, is pleased to announce that its most recently completed clinical trial was selected for presentation at the 72nd Scientific Sessions of the American Diabetes Association (ADA) which will be held June 8-12, 2012 in Philadelphia, PA. The study will be presented in an oral presentation that is currently scheduled on Friday, June 8 at 5:45 PM ET.
The presentation entitled "Transdermal Continuous Glucose Monitoring Following Skin Permeation," by Wayne Menzie, Echo's Director of Technology and Clinical Development, will provide an expanded analysis of data collected from subjects with either type 1 or type 2 diabetes during Echo's recent clinical trial of its Symphony tCGM System.
Additionally, Echo Therapeutics expects to release preliminary results from its Symphony tCGM studies in critical care patients in the next month.
"We are excited to share these results on the opening day of ADA, the largest gathering of healthcare professionals in the fight against diabetes. We value this opportunity for engagement with experts in the field of diabetes research, care and services," stated Patrick Mooney, M.D., Echo's Chairman and CEO. "We believe the results of the diabetes clinical study combined with supporting data in our current critical care studies will further highlight the positive impact Symphony may have for diabetes and critical care patients."
More than 25 million children and adults in the U.S., or over 8 percent of the population, have diabetes, according to the 2011 National Diabetes Fact Sheet.
|SOURCE Echo Therapeutics, Inc.|
Copyright©2010 PR Newswire.
All rights reserved